Brentuximab

Brentuximab is a monoclonal antibody targeting CD30. Brentuximab is conjugated with monomethyl auristatin E (MMAE) (HY-15162) to form the antibody-drug conjugate Brentuximab vedotin (HY-P99107), which can induce apoptosis in primary effusion lymphoma cells. Brentuximab vedotin exhibits antitumor activity with an IC50 of 10 nM against human CD30+ cancer cells[1][2][3].

Product Specifications

CAS Number

[2088770-90-3]

UNSPSC

12352203

Target

ADC Antibody; TNF Receptor

Type

Inhibitory Antibodies

Related Pathways

Antibody-drug Conjugate/ADC Related; Apoptosis

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/brentuximab.html

Purity

99.64

Solubility

10 mM in DMSO

Smiles

[Brentuximab]

Molecular Weight

(145.48 kDa)

References & Citations

[1]Bhatt S, et al. CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma. Blood. 2013 Aug 15;122 (7) :1233-42. |[2]Chen R W, et al. Inhibition of MDR1 overcomes brentuximab vedotin resistance in Hodgkin lymphoma cell line model and is synergistic with brentuximab vedotin in mouse xenograft model[J]. Blood, 2016, 128 (22) : 752.|[3]Wang Z, et al. CCR4-IL2 bispecific immunotoxin is more effective than brentuximab for targeted therapy of cutaneous T-cell lymphoma in a mouse CTCL model. FEBS Open Bio. 2023 Jul;13 (7) :1309-1319.